Hyderabad, June 4 (PTI): Biological E Limited on Saturday announced that its COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India (DCGI) as a heterologous booster dose. A press release from the vaccine maker said the Corbevax can be administered as a booster dose to individuals aged 18 years and above after six months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for restricted use in emergency situation. BE’s Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country, it said. Recently, BE furnished its clinical trials data to the DCGI which after a detailed evaluation and deliberations with Subject Experts Committee, granted their approval for administering Corbevax as a heterologous booster dose to people who have been vaccinated. BE’s clinical trial data showed that its Corbevax booster dose provided significant enhancement in immune response and exc
This means that those above the age of 18 who have been fully vaccinated with Covishield or Covaxin vaccines can take Biological E Limited’s Corbevax as their booster or third shot.
Biological E. Limited, a Hyderabad-based pharmaceutical and vaccines company, on Saturday, announced that its Corbevax COVID-19 vaccine has been approved by the